EUVIMEDOpdag EUVIMED
Leserbrief

Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa

Lei Shao, Dao-Qing Zhong, Yu-Mei Liu, Jian-Qin Wang

International Journal of Dermatology · 2023

DOI: 10.1111/ijd.16752 ↗

At a glance

Leserbrief in International Journal of Dermatology, 2023. Written by Lei Shao and 3 co-authors. Institution: Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China. Major MEDLINE topics: Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa. Cited 4 times so far (Crossref); 5 references. Funded by: Science and Technology General guidance project of Guangzhou Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

References 1 Friedman B, Chen B, Latimer A, Valento M. Iatrogenic pediatric hydroxocobalamin overdose. Am J Emerg Med. 2019;37:1394.e1–2. https://doi.org/10.1016/j.ajem.2019.04.012 2 Cyanokit package insert. Meridian Medical Technologies. www. cyanokit.com 3 Forsyth J, Mueller P, Becker C, Osterloh J, Benowitz N, Rumack B, et al. Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. J Toxicol Clin Toxicol. 1993;31(2):277–94. https://doi.org/10.3109/ 15563659309000395 4 Wong S, Pudek M, Li D. Wine-colored plasma and urine from hydroxocobalamin treatment. J Gen Intern Med. 2016;32(2):225– 6. https://doi.org/10.1007/s11606-016-3782-3 5 Foley E, Lombardi R, Patel V. Hydroxycobalamin-induced pigmented effluent during dialysis. Kidney Int. 2021;99(6):1503. https://doi.org/10.1016/j.kint.2020.09.011

Subjects

MeSH terms (MEDLINE)

Epidermolysis Bullosa DystrophicaEpidermolysis BullosaHumansAntibodies, Monoclonal, HumanizedCollagen Type VII

Substances

dupilumabAntibodies, Monoclonal, HumanizedCollagen Type VII

Authors and institutions

  • Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, China.
  • Institute of Dermatology, Guangzhou Medical University, Guangzhou, China.

Funding

  • Science and Technology General guidance project of Guangzhou Health

Cite

APA

Shao, L., Zhong, D. Q., Liu, Y. M., & Wang, J. Q. (2023). Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa. International Journal of Dermatology. https://doi.org/10.1111/ijd.16752

Vancouver

Shao L, Zhong DQ, Liu YM, Wang JQ. Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa. International Journal of Dermatology. 2023. doi:10.1111/ijd.16752

BibTeX
@article{Shao2023,
  author = {Shao, Lei and Zhong, Dao-Qing and Liu, Yu-Mei and Wang, Jian-Qin},
  title = {Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa},
  journal = {International Journal of Dermatology},
  year = {2023},
  doi = {10.1111/ijd.16752}
}
Start for free →